Clinical Trial Search

Primary: Time to Dispensing of Inappropriate Medication Prescription — 76.7; 77.9; 77.5 Percentage of Cumulative Incidence — p=0.76

Primary: Mean Overnight Growth Hormone Levels — 0.85; 0.84 ng/mL — p=0.918

Primary: The Change in Amount of Insulin Like Growth Factor (IGF-I) Generated (Day 8-day 1) — 115; 129 mcg/L

Primary: Change in Progesterone Sensitivity Index Before and After Metformin Treatment. — -4.12; -4.29 % change in LH pulses/day 7 P4 level

Primary: Overnight Mean Growth Hormone Secretion After 2 Weeks of Study Drug — 0.23; 0.07; 1.24 ng/mL — p=0.01

Primary: PP1- Serum IGF-1 Levels, DXA, Resting Metabolic Rate, Total Body Water, 3-D Echo, Cardiac MRI, Dobutamine Stress Echocardiogram, Ergometry, General Health Assessment…

Primary: Steady-state Plasma Glucose (SSPG) — 130; 139 mg/dL — p=0.01

Primary: Change in Sodium Levels From Start of Treatment With Tolvaptan Until Hospital Discharge — 10.3 mmol/L

Primary: Maximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration. — 3.6; 5.3; 7.9 mmol/L

Primary: Mean Baseline GH Concentration — 0.23; 0.096 ug/L — p=<0.05

Primary: Arginine-stimulated Insulin Secretion With and Without GLP-1 Blockade — 320.1; 243.4; 280; 251.2 pmol/L — p=< 0.05

Primary: Inappropriate Antibiotic Prescribing for Patients With Acute Respiratory Infections (ARI) — 33.7; 52.7 inappropriate prescribing events

Primary: 24 Hour Average Plasma Growth Hormone Concentration — 0.4; 1.2; 4.1 ng/mL

Primary: Phosphocreatine Recovery — 0.74 correlation coefficient — p=0.02

Primary: Number of Patients Managed According to the SEOM Algorithm (as a Result Adherence to the Algorithm Will be the % of These Patients Among the Total Number of Patients)…